Spots Global Cancer Trial Database for Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
Official Title: A Phase IIIB, Randomized, Active Controlled Open-Label Study Of Sunitinib (Sutent) 37.5 Mg Daily Vs Imatinib Mesylate 800 Mg Daily In The Treatment Of Patients With Gastrointestinal Stromal Tumors (GIST) Who Have Had Progressive Disease While On 400 Mg Daily Of Imatinib
Study ID: NCT00372567
Conditions
Study Description
Brief Summary: A phase IIIb study of patients with gastrointestinal stromal tumors who have had progressive disease while on 400 mg imatinib. Patients will be randomly assigned to either sunitinib 37.5 mg daily or imatinib 800 mg daily. This study will find out the benefits and potential side effects of taking sunitinib or imatinib for approximately one year.
Detailed Description: The study prematurely discontinued on July 27, 2009 due to poor recruitment and operational futility as a result of changes in clinical practice. There were no safety or efficacy concerns regarding the study in the decision to terminate the trial.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Pfizer Investigational Site, Detroit, Michigan, United States
Pfizer Investigational Site, Farmington Hills, Michigan, United States
Pfizer Investigational Site, Creve Coeur, Missouri, United States
Pfizer Investigational Site, St. Louis, Missouri, United States
Pfizer Investigational Site, St. Peters, Missouri, United States
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
Pfizer Investigational Site, Goettingen, , Germany
Pfizer Investigational Site, Hamburg, , Germany
Pfizer Investigational Site, Lai Chi Kok, Kowloon, Hong Kong
Pfizer Investigational Site, Tuen Mun, New Territories, Hong Kong
Pfizer Investigational Site, Hong Kong, , Hong Kong
Pfizer Investigational Site, Bologna, , Italy
Pfizer Investigational Site, Milano, , Italy
Pfizer Investigational Site, San Giovanni Rotondo, , Italy
Pfizer Investigational Site, Seoul, , Korea, Republic of
Pfizer Investigational Site, Seoul, , Korea, Republic of
Pfizer Investigational Site, Seoul, , Korea, Republic of
Pfizer Investigational Site, Barcelona, , Spain
Pfizer Investigational Site, Valencia, , Spain
Pfizer Investigational Site, Glasgow, , United Kingdom
Pfizer Investigational Site, Leeds, , United Kingdom
Pfizer Investigational Site, London, , United Kingdom
Pfizer Investigational Site, London, , United Kingdom
Pfizer Investigational Site, London, , United Kingdom
Pfizer Investigational Site, Manchester, , United Kingdom
Contact Details
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
